|
|
||||||||||
|
J Am Coll Cardiol, 2003; 42:1188-1195, doi:10.1016/S0735-1097(03)00944-6 © 2003 by the American College of Cardiology Foundation |
,*



* Department of Cardiology, Ochsner Clinic Foundation, New Orleans, Louisiana, USA
Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Division of Cardiology, Mayo Clinic Foundation, Rochester, Minnesota, USA
Lenox Hill Heart and Vascular Institute, New York, New York, USA
|| Merck, West Point, Pennsylvania, USA
¶ Riverside Methodist Hospital, Columbus, Ohio, USA
# Department of Biostatistics and Epidemiology, The Cleveland Clinic Foundation, Cleveland, Ohio, USA
Manuscript received December 12, 2002; revised manuscript received April 22, 2003, accepted May 9, 2003.
* Reprint requests and correspondence: Dr. David J. Moliterno, Department of Cardiovascular Medicine, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Desk F25, Cleveland, Ohio 44195.
molited{at}ccf.org
OBJECTIVES: We sought to examine if clopidogrel treatment initiated before coronary stenting improved clinical outcomes among patients receiving aspirin and a glycoprotein (GP) IIb/IIIa inhibitor.
BACKGROUND: Antiplatelet therapy plays a pivotal role in contemporary percutaneous coronary interventions (PCI).
METHODS: Outcomes among 4,809 patients randomized to tirofiban or abciximab during PCI with stent placement were compared according to whether they received 300 mg of clopidogrel before PCI (93.1%) versus immediately after the procedure.
RESULTS: The 30-day primary composite end point (death, myocardial infarction [MI], or urgent target vessel revascularization [TVR]) was lower among clopidogrel-pretreated patients (6.6% vs. 10.4%, p = 0.009), mainly because of reduction of MI (6.0% vs. 9.5%, p = 0.012). The benefit of clopidogrel pretreatment was sustained at six months (death, MI, any TVR: 14.6% vs. 19.8%, HR = 0.71, p = 0.010), and this was due mainly to lowering of death and MI (7.8% vs. 13.0%, p = 0.001). At one year, clopidogrel pretreatment was associated with a lower mortality rate (1.7% vs. 3.6%, p = 0.011). Because clopidogrel pretreatment was not randomized, multivariable and propensity analyses were performed. After adjusting for baseline heterogeneity, clopidogrel pretreatment was an independent predictor for death or MI at 30 days (HR = 0.63, p = 0.012) and at six months (HR = 0.61, p = 0.003), and survival at one year (HR = 0.53, p = 0.044). No excess in 30-day bleeding events was noted with clopidogrel pretreatment.
CONCLUSIONS: Among patients undergoing coronary stent placement with aspirin and a GP IIb/IIIa inhibitor, clopidogrel pretreatment is associated with a reduction of death and MI irrespective of the type of GP IIb/IIIa inhibitor used.
| ||||||||||||||||||||||||
This article has been cited by other articles:
![]() |
J. Nappi Benefits and limitations of current antiplatelet therapies Am. J. Health Syst. Pharm., July 1, 2008; 65(13_Supplement_5): S5 - S10. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Kereiakes and P. A. Gurbel Peri-Procedural Platelet Function and Platelet Inhibition in Percutaneous Coronary Intervention J. Am. Coll. Cardiol. Intv., April 1, 2008; 1(2): 111 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, J.-P. Bassand, C. W. Hamm, D. Ardissino, E. Boersma, A. Budaj, F. Fernandez-Aviles, K. A.A. Fox, D. Hasdai, E. M. Ohman, et al. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes: The Task Force for the Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of the European Society of Cardiology Eur. Heart J., July 1, 2007; 28(13): 1598 - 1660. [Full Text] [PDF] |
||||
![]() |
F.-J. Neumann, A. Kastrati, and G. Schwarzer New aspects in the treatment of acute coronary syndromes without ST-elevation: ICTUS and ISAR-COOL in perspective Eur. Heart J. Suppl., February 1, 2007; 9(suppl_A): A4 - A10. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. F. Bertrand, R. De Larochelliere, J. Rodes-Cabau, G. Proulx, O. Gleeton, C. Manh Nguyen, J.-P. Dery, G. Barbeau, B. Noel, E. Larose, et al. A Randomized Study Comparing Same-Day Home Discharge and Abciximab Bolus Only to Overnight Hospitalization and Abciximab Bolus and Infusion After Transradial Coronary Stent Implantation Circulation, December 12, 2006; 114(24): 2636 - 2643. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. B. Borden and D. P. Faxon Facilitated Percutaneous Coronary Intervention J. Am. Coll. Cardiol., September 19, 2006; 48(6): 1120 - 1128. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Chaer, J. A. Graham, and L. Mureebe Platelet Function and Pharmacologic Inhibition Vascular and Endovascular Surgery, August 1, 2006; 40(4): 261 - 267. [Abstract] [PDF] |
||||
![]() |
S. R. Steinhubl, P. B. Berger, D. M. Brennan, E. J. Topol, and for the CREDO Investigators Optimal Timing for the Initiation of Pre-Treatment With 300 mg Clopidogrel Before Percutaneous Coronary Intervention J. Am. Coll. Cardiol., March 7, 2006; 47(5): 939 - 943. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Herrmann Peri-procedural myocardial injury: 2005 update Eur. Heart J., December 1, 2005; 26(23): 2493 - 2519. [Abstract] [Full Text] [PDF] |
||||
![]() |
K D Dawkins, T Gershlick, M de Belder, A Chauhan, G Venn, P Schofield, D Smith, J Watkins, H H Gray, and Joint Working Group on Percutaneous Coronary Inter Percutaneous coronary intervention: recommendations for good practice and training Heart, December 1, 2005; 91(suppl_6): vi1 - vi27. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. Moliterno and S. R. Steinhubl Clopidogrel for Percutaneous Coronary Revascularization: Time for More Pretreatment, Retreatment, or Both? JAMA, September 14, 2005; 294(10): 1271 - 1273. [Full Text] [PDF] |
||||
![]() |
M. S. Sabatine, C. P. Cannon, C. M. Gibson, J. L. Lopez-Sendon, G. Montalescot, P. Theroux, B. S. Lewis, S. A. Murphy, C. H. McCabe, E. Braunwald, et al. Effect of Clopidogrel Pretreatment Before Percutaneous Coronary Intervention in Patients With ST-Elevation Myocardial Infarction Treated With Fibrinolytics: The PCI-CLARITY Study JAMA, September 14, 2005; 294(10): 1224 - 1232. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. P. Giugliano and E. Braunwald The Year in Non--ST-Segment Elevation Acute Coronary Syndromes J. Am. Coll. Cardiol., September 6, 2005; 46(5): 906 - 919. [Full Text] [PDF] |
||||
![]() |
I. Hunt, L. J.H. Blows, and S. J. Patel Why clopidogrel failed to inhibit platelet function early after coronary artery bypass surgery: To load or not to load, and is it a question of resistance? J. Thorac. Cardiovasc. Surg., May 1, 2005; 129(5): 1197 - 1197. [Full Text] [PDF] |
||||
![]() |
K. L Longstreth and J. R Wertz High-Dose Clopidogrel Loading in Percutaneous Coronary Intervention Ann. Pharmacother., May 1, 2005; 39(5): 918 - 922. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Patti, G. Colonna, V. Pasceri, L. L. Pepe, A. Montinaro, and G. Di Sciascio Randomized Trial of High Loading Dose of Clopidogrel for Reduction of Periprocedural Myocardial Infarction in Patients Undergoing Coronary Intervention: Results From the ARMYDA-2 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Circulation, April 26, 2005; 111(16): 2099 - 2106. [Abstract] [Full Text] [PDF] |
||||
![]() |
Authors/Task Force Members, S. Silber, P. Albertsson, F. F. Aviles, P. G. Camici, A. Colombo, C. Hamm, E. Jorgensen, J. Marco, J.-E. Nordrehaug, et al. Guidelines for Percutaneous Coronary Interventions: The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology Eur. Heart J., April 2, 2005; 26(8): 804 - 847. [Full Text] [PDF] |
||||
![]() |
M. Valgimigli, G. Percoco, D. Barbieri, F. Ferrari, G. Guardigli, G. Parrinello, O. Soukhomovskaia, and R. Ferrari The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: The advance trial J. Am. Coll. Cardiol., July 7, 2004; 44(1): 14 - 19. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. J. van der Heijden, I. C. D. Westendorp, R. K. Riezebos, F. Kiemeneij, T. Slagboom, L. R. van der Wieken, and G.-J. Laarman Lack of efficacy of clopidogrel pre-treatment in the prevention of myocardial damage after elective stent implantation J. Am. Coll. Cardiol., July 7, 2004; 44(1): 20 - 24. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Rozenman For how long should treatment with clopidogrel be continued after coronary stent implantation? J. Am. Coll. Cardiol., April 7, 2004; 43(7): 1331 - 1331. [Full Text] [PDF] |
||||
![]() |
W.-H. Chen, P.-Y. Lee, W. Ng, H.-F. Tse, and C.-P. Lau Aspirin resistance is associated with a high incidence of myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel pretreatment J. Am. Coll. Cardiol., March 17, 2004; 43(6): 1122 - 1126. [Abstract] [Full Text] [PDF] |
||||
![]() |
More Support for Clopidogrel Before PCI Journal Watch Cardiology, December 12, 2003; 2003(1212): 4 - 4. [Full Text] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |